84348-39-0

Basic information

• Product Name: N-Boc-4-Methylene-L-proline Methyl Ester
• Synonyms: N-Boc-4-Methylene-L-proline Methyl Ester;(S)-1-tert-butyl 2-Methyl 4-Methylenepyrrolidine-1,2-dicarboxylate;(2S)-4-Methylene-1,2-pyrrolidinedicarboxylic Acid 1-(1,1-DiMethylethyl) 2-Methyl Ester;1,2-Pyrrolidinedicarboxylic acid, 4-Methylene-, 1-(1,1-diMethylethyl) 2-Methyl ester, (2S)-;(S)-1-(Tert-butoxycarbonyl)-2-Methyl-4-Methylenepyrrolidine-2-carboxylic acid;1-(tert-butyl) 2-methyl (S)-4-methylenepyrrolidine-1,2-dicarboxylate;-1-tert-Butyl 2-methyl 4-methylenepyrrolidine-1,2-dicarboxylate;1-O-tert-butyl 2-O-methyl (2S)-4-methylidenepyrrolidine-1,2-dicarboxylate
• CAS NO: 84348-39-0
• Molecular Formula: C₁₂H₁₉NO₄
• Molecular Weight: 241.28356
• Product Categories: Amino Acids & Derivatives;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 84348-39-0.mol
• Article Data: 46

Chemical Properties

• Boiling Point: 302.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -3.56±0.40(Predicted)
• CAS DataBase Reference: N-Boc-4-Methylene-L-proline Methyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-4-Methylene-L-proline Methyl Ester(84348-39-0)
• EPA Substance Registry System: N-Boc-4-Methylene-L-proline Methyl Ester(84348-39-0)

Safety Data

• Hazardous Substances Data: 84348-39-0(Hazardous Substances Data)

Usage

Uses

N-Boc-4-Methylene-L-proline Methyl Ester is an L-proline derivative with antibacterial activity used in the preparation of novel peptide deformylase inhibitors.

Upstream product

• 1779-49-3 Methyltriphenylphosphonium bromide 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 
• 19493-09-5 Methylenetriphenylphosphorane 
• 67-56-1 methanol 
• 84348-38-9 (S)-1-(tert-butoxycarbonyl)-4-methylenepyrrolidine-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 51-35-4 4R-4-hydroxyproline 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 75-24-1 trimethylaluminum 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 27200-84-6 methyl triphenylphosphonium bromide 
• 186581-53-3 diazomethane 
• 593-71-5 Chloroiodomethane 

Downstream Products

• 109606-56-6 1-tert-butyl 2-methyl (2S)-4-methylpyrrolidine-1,2-dicarboxylate 
• 1268819-47-1 C₂₂H₂₉N₃O₄ 
• 1268819-48-2 C₂₂H₂₈FN₃O₄ 
• 1256162-56-7 C₂₃H₃₂N₂O₆ 
• 1256162-57-8 C₂₂H₃₀N₂O₆ 
• 1268819-53-9 C₂₄H₃₂N₂O₆ 
• 1256162-68-1 C₂₆H₃₇N₃O₆ 
• 1256162-64-7 C₂₈H₃₅N₃O₅ 
• 1256162-66-9 C₂₈H₃₄FN₃O₅ 
• 1268819-36-8 C₂₈H₃₅N₃O₆ 
• 1256162-58-9 C₂₇H₃₃FN₄O₅ 
• 1256162-65-8 (S)-1-((R)-2-((N-hydroxyformamido)methyl)hexanoyl)-4-methylene-N-phenylpyrrolidine-2-carboxamide 
• 1256162-59-0 C₂₇H₃₃FN₄O₆ 
• 1256162-61-4 C₂₆H₃₄N₄O₅S 

Relevant articles and documents

Erratum: Development of a manufacturing process for an HCV protease inhibitor candidate molecule (Organic Process Research and Development (2015) 19:1 (270?283) DOI: 10.1021/op500210w)

-

VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS

The present invention relates to the field of oncology, laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking; to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.

MASP INHIBITORY COMPOUNDS AND USES THEREOF

The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.